Skip to content
Announcement:

Latest Publication: Read our teams’ latest paper in Antibiotics, showing reduced nephrotoxicity of a novel formulation of polymyxin B compared to the clinical formulation using a validated primary human proximal tubule cell model.

Updates: Update

11th June, 2024

Press Release : Newcells Biotech strengthens executive and US team with key appointments

Dr Valeria Chichagova appointed as Director of Technology, Dr Colin Brown as Chief Scientific Officer, and Professor Lyle Armstrong as Scientific Advisor New US commercial appointments also announced…

Read update
29th August, 2023

Latest Advances in CAR-T Therapy with novel HLA-typed in vitro cell tools

CAR-T Therapy CAR-T Therapy is a form of immunotherapy that harnesses the power of the patient’s immune system to target and eliminate cancer cells. It involves ex-vivo genetic engineering of…

Read update
28th July, 2023

MPS summit highlights

About the conference: MPS summit The MPS summit is a small but buzzing conference, where scientists from the pharma industry, academia and microchip manufacturers gather to discuss the latest advances…

Read update
Accelerate preclinical testing
15th June, 2022

Gene therapy vectors: Preclinical testing with retinal organoids

Adeno Associated Virus (AAV) vectors have emerged as the most successful retinal gene therapy vectors following the FDA approval of Luxturna in 2017. This new gene therapy product is…

Read update
Organ on chip
31st May, 2022

Organ-on-a-chip: the next generation tool for drug development?

Organ-on-a-chip (OoC) or Microphysiological systems (MPS) are microfluidic devices providing a controlled microenvironment for miniaturised tissues mimicking physiological architecture and function of human tissues and organs. The application of dynamic…

Read update
Glomerulus surrounded by convoluted tubules
11th March, 2022

Why is an in vitro model of the glomerulus desperately needed?

In most cases, once the kidney’s function is limited, the only treatment options are dialysis and kidney transplant. The absence of effective drugs to treat kidney disease is partly…

Read update
17th November, 2023

An insight into R&D at Newcells Biotech with Dr Fiona Leslie, PhD, Lung platform scientist

Can you tell us a little bit about your professional journey and how you made the transition to industry? I have an undergraduate Degree in biomedical science and also completed…

Read update
9th November, 2023

Mr Terry Pizzie joins Newcells Biotech Board as non-executive director

Terry’s career in the life science industry spans more than 30 years. He was the CEO of Cambridge based Horizon Discovery Plc, a public company listed on the UK…

Read update
12th October, 2023

Imaging propels our kidney assays to the next level

We recently expanded our imaging capability with the purchase of an ImageXpress Pico high content imaging (HCI) system from Molecular Devices. Since then, our technical teams have been busy…

Read update
29th August, 2023

Latest Advances in CAR-T Therapy with novel HLA-typed in vitro cell tools

CAR-T Therapy CAR-T Therapy is a form of immunotherapy that harnesses the power of the patient’s immune system to target and eliminate cancer cells. It involves ex-vivo genetic engineering of…

Read update
28th July, 2023

MPS summit highlights

About the conference: MPS summit The MPS summit is a small but buzzing conference, where scientists from the pharma industry, academia and microchip manufacturers gather to discuss the latest advances…

Read update
30th June, 2023

3rd ILD Summit Highlights

About the conference : ILD Summit The ILD Summit is a niche industry dedicated conference focussed on advancing therapies for progressive fibrosing interstitial lung diseases (ILD). This year’s conference was the…

Read update

Get our latest updates straight to your inbox